Elamipretide confirmatory trial appears after accelerated approval
Why the 4TAZPower trial matters for Forzinity's narrow Barth syndrome approval.
Published by PeptideFactSheets. Sources and methods · Research reporting, not clinical review.
The milestone
ClinicalTrials.gov lists 4TAZPower, a Phase 3b/4 randomized, double-blind, placebo-controlled study in people with genetically confirmed Barth syndrome.
The registry describes the trial as a post-marketing confirmatory study for elamipretide after Forzinity's accelerated FDA approval. The study record does not show public results.
Why it matters
- Forzinity's FDA approval was accelerated and narrow: it covers improving muscle strength in adults and pediatric patients with Barth syndrome who weigh at least 30 kilograms.
- Accelerated approval can rest on an endpoint considered reasonably likely to predict clinical benefit. The FDA announcement and label both state that continued approval may depend on confirmatory evidence.
- A registered confirmatory trial helps readers distinguish the approved intermediate-endpoint claim from broader mitochondrial, fatigue, performance, or healthy-aging claims that remain unproven.
What it means for readers
- The 4TAZPower record describes how researchers plan to test whether the muscle-strength finding translates into a confirmed benefit for people with Barth syndrome.
- Nothing changed about the approved use: Forzinity remains approved only for the labeled Barth syndrome population, not for general mitochondrial support or athletic performance.
- The trial registration is not a result. It should not be read as proof that patient-centered benefit has been verified.
What remains uncertain?
- Whether the confirmatory trial will start, complete, and produce public results
- Whether functional outcomes will verify a patient-centered clinical benefit
- How the benefit-risk profile will look with more participants and longer follow-up
- Whether any other mitochondrial-disease research will support separate indications
Related fact sheets
Source links
- 1clinical trialsClinicalTrials.gov: 4TAZPower
Registered post-marketing confirmatory trial for elamipretide in genetically confirmed Barth syndrome.
- 2fdaFDA prescribing information: Forzinity
Official label describing the approved use, accelerated-approval basis, and confirmation requirement.
- 3fdaFDA accelerated approval announcement
FDA announcement describing the approval and post-approval trial requirement.